enGene director receives option grant for 31,000 shares

enGene Therapeutics Inc. director Michael Thomas Heffernan reported receiving a stock option grant covering 31,000 Common Shares.

Rhea-AI Filing Summary

enGene Therapeutics Inc. director Michael Thomas Heffernan reported receiving a stock option grant covering 31,000 Common Shares. The option has an exercise price of $1.75 per share, giving him the right to buy shares at that price in the future.

The option was granted as a compensation award and expires on June 16, 2036. It vests fully on the earlier of the first anniversary of the vesting commencement date, which was June 9, 2026, or the company’s 2027 annual meeting of shareholders.

Insider Trade Summary

Grant/Award: 31,000 shares

Grant/Award 1 txn

Insider Heffernan Michael Thomas

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	31,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 31,000 contracts (Direct)

Footnotes (1)

1. F1. This option vests fully on the earlier of (i) the first anniversary of the vesting commencement date, which was June 9, 2026 or (ii) the registrant's 2027 annual meeting of shareholders.

Key Figures

Option grant size: 31,000 shares Exercise price: $1.75 per share Option cost at grant: $0.00 per share +2 more

5 metrics

Option grant size 31,000 shares Underlying Common Shares in stock option award

Exercise price $1.75 per share Stock option conversion or exercise price

Option cost at grant $0.00 per share Price paid for the option itself on grant

Expiration date June 16, 2036 Option expiration for the 31,000-share grant

Shares after transaction 31,000 derivative shares Total options held following this reported grant

Key Terms

Stock Option (Right to Buy), vesting commencement date, annual meeting of shareholders, Common Shares, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

vesting commencement date financial

"the first anniversary of the vesting commencement date, which was June 9, 2026"

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

annual meeting of shareholders financial

"the registrant's 2027 annual meeting of shareholders"

A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.

Common Shares financial

"underlying_security_title: Common Shares"

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Michael Thomas Heffernan report in this enGene (ENGN) Form 4?

Michael Thomas Heffernan reported receiving a stock option grant for 31,000 Common Shares of enGene Therapeutics Inc. The option was granted as compensation, not bought on the open market, and gives him the right to purchase shares at a fixed exercise price.

How many enGene (ENGN) shares are covered by Heffernan’s new stock option?

The reported stock option grant covers 31,000 underlying Common Shares of enGene Therapeutics Inc. This means he may acquire up to 31,000 shares by exercising the option, subject to its vesting schedule and the stated expiration date.

What is the exercise price and expiration date of Heffernan’s enGene (ENGN) option?

The option has an exercise price of $1.75 per share and expires on June 16, 2036. Heffernan can choose to exercise the option before that expiration date, once it has fully vested under the described vesting conditions.

When does Michael Heffernan’s enGene (ENGN) option vest according to the Form 4?

The option vests fully on the earlier of two events: the first anniversary of the vesting commencement date, which was June 9, 2026, or enGene’s 2027 annual meeting of shareholders. Full vesting is required before the entire grant can be exercised.

Is Heffernan’s enGene (ENGN) Form 4 transaction a purchase or a compensation grant?

The Form 4 shows a compensation-related grant, not an open-market purchase. The transaction is coded as a grant or award acquisition, with a price per share of $0.00 for the option itself and a stated exercise price of $1.75 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/17/2026 - 05:38 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Heffernan Michael Thomas

(Last) (First) (Middle)

C/O 4868 RUE LEVY, SUITE 220

(Street)

SAINT-LAURENT H4R 2P1

(City) (State) (Zip)

QUEBEC, CANADA

(Country)

2. Issuer Name and Ticker or Trading Symbol
enGene Therapeutics Inc. [ ENGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.75	06/16/2026		A		31,000		(1)	06/16/2036	Common Shares	31,000	$0	31,000	D

Explanation of Responses:

1. This option vests fully on the earlier of (i) the first anniversary of the vesting commencement date, which was June 9, 2026 or (ii) the registrant's 2027 annual meeting of shareholders.

	/s/ Lee Giguere, as attorney-in-fact for the Reporting Person	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)